Form 4: BioMarin Director Receives Equity Grant

Director Mark J. Enyedy was granted 7,490 restricted stock units by BioMarin Pharmaceutical Inc.

Summary

• Director Mark J. Enyedy acquired 7,490 shares of BioMarin Pharmaceutical Inc. (BMRN) common stock.
• The transaction occurred on June 2, 2026, in the form of a restricted stock unit (RSU) grant.
• The shares were acquired at a price of $0, as they represent equity compensation.
• Following this transaction, the reporting person's total beneficial ownership is 21,040 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term oversight and alignment with shareholder value in the biotechnology sector.

Comparison to Industry Standards

• The grant of restricted stock units to directors is a standard practice among mid-to-large cap pharmaceutical companies to ensure board retention and alignment.
• The transaction size is consistent with typical director compensation packages for companies of BioMarin's market capitalization.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

BioMarin, BMRN, Form 4, Insider Trading, Equity Compensation, Director